Coronavirus in human diseases: Mechanisms and advances in clinical treatment

被引:20
|
作者
Lin, Panpan [1 ]
Wang, Manni [1 ]
Wei, Yuquan [1 ]
Kim, Taewan [2 ]
Wei, Xiawei [1 ]
机构
[1] Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Lab Aging Res & Canc Drug Target,State Key Lab Bi, Chengdu 610041, Peoples R China
[2] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
来源
MEDCOMM | 2020年 / 1卷 / 03期
关键词
clinical treatments; COVID-19; human coronaviruses; MERS; SARS; RESPIRATORY SYNDROME CORONAVIRUS; INFECTIOUS-BRONCHITIS-VIRUS; PAPAIN-LIKE PROTEASE; RECEPTOR-BINDING DOMAIN; ANGIOTENSIN-CONVERTING ENZYME; SARS-ASSOCIATED CORONAVIRUS; INNATE ANTIVIRAL RESPONSE; HUMAN MONOCLONAL-ANTIBODY; DIPEPTIDYL-PEPTIDASE IV; SMALL MEMBRANE-PROTEIN;
D O I
10.1002/mco2.26
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Coronaviruses (CoVs), a subfamily of coronavirinae, are a panel of single-stranded RNA virus. Human coronavirus (HCoV) strains (HCoV-229E, HCoV-OC43, HCoV-HKU1, HCoV-NL63) usually cause mild upper respiratory diseases and are believed to be harmless. However, other HCoVs, associated with severe acute respiratory syndrome, Middle East respiratory syndrome, and COVID-19, have been identified as important pathogens due to their potent infectivity and lethality worldwide. Moreover, currently, no effective antiviral drugs treatments are available so far. In this review, we summarize the biological characters of HCoVs, their association with human diseases, and current therapeutic options for the three severe HCoVs. We also highlight the discussion about novel treatment strategies for HCoVs infections.
引用
收藏
页码:270 / 301
页数:32
相关论文
共 50 条